Neurofibromatosis News and Research RSS Feed - Neurofibromatosis News and Research

Neurofibromatosis is a genetic condition in which tumors form on the nerves of the inner ear and cause loss of hearing and balance. Tumors may also occur in the brain and on nerves in the skull and spinal cord, and may cause loss of speech, eye movement, and the ability to swallow. Also called acoustic neurofibromatosis and NF2.
Southern Society bestows 2016 Clinical Science Young Investigator Award to Stansfield

Southern Society bestows 2016 Clinical Science Young Investigator Award to Stansfield

Dr. Brian K. Stansfield, neonatologist at Children's Hospital of Georgia and a 2004 graduate of the Medical College of Georgia at Augusta University, has received the 2016 Clinical Science Young Investigator Award from the Southern Society for Pediatric Research. [More]
Cancer causing genetic condition risk in children lower than previously thought

Cancer causing genetic condition risk in children lower than previously thought

The odds of children having a genetic condition which causes learning difficulties and tumours have been dramatically cut, thanks to genetic analysis led by The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust [More]
UAB lab to offer new tests for genetic diseases using next-generation sequencing

UAB lab to offer new tests for genetic diseases using next-generation sequencing

The Medical Genomics Laboratory at the University of Alabama at Birmingham is expanding its technological array with a new panel of diagnostic tests for genetic diseases known as neurofibromatoses and rasopathies. Beginning April 18, the UAB lab will offer new tests using the technique called customized deep-coverage, next-generation sequencing or NGS. [More]
Anticancer drug restores hearing in neurofibromatosis patients

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing. [More]
UAB research explores neurofibromatosis type 1

UAB research explores neurofibromatosis type 1

It is easy to tell a medical research story that has a simple and dramatic moment. But disease is often much more complex, and the work to understand it can be painstaking. A vivid example of that is seen in the University of Alabama at Birmingham Medical Genomics Laboratory, headed by Ludwine Messiaen, Ph.D., professor of genetics. This lab offers clinical genetic testing for a broad array of common and rare genetic disorders. [More]
Neurocutaneous disorders affect skin, nervous system

Neurocutaneous disorders affect skin, nervous system

One of the most common genetic disorders is a condition called neurofibromatosis, which causes brown spots on the skin and benign tumors on the brain, spinal cord and other parts of the nervous system. [More]
New study reveals why some vestibular schwannomas cause hearing loss

New study reveals why some vestibular schwannomas cause hearing loss

A new study at Massachusetts Eye and Ear showed that in some cases of vestibular schwannoma, a sometimes-lethal tumor often associated with neurofibromatosis 2 (NF2), secretions from the tumor contain toxic molecules that damage the inner ear. [More]
MCG researchers explore how neurofibromatosis puts young patients at risk for cardiovascular disease

MCG researchers explore how neurofibromatosis puts young patients at risk for cardiovascular disease

It's a fairly common genetic condition that can surface as a series of dark skin spots and result in a host of maladies from tumors to premature cardiovascular disease. Medical College of Georgia researchers hope their studies of how neurofibromatosis 1, or NF1, can dangerously thicken or thin blood vessel walls will one day help physicians better identify and treat these young patients at cardiovascular risk. [More]
FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans. [More]
Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases. [More]
UT Southwestern surgeons help pioneer minimally invasive ear surgery

UT Southwestern surgeons help pioneer minimally invasive ear surgery

UT Southwestern Medical Center surgeons are helping to pioneer a trend that extends the advantages and benefits of minimally invasive surgery to patients who need middle ear surgery. [More]
UCSF researchers lead $10 million research project on pediatric cancer

UCSF researchers lead $10 million research project on pediatric cancer

Researchers at UC San Francisco are leading a five-year, $10 million research project dedicated to pediatric cancer, funded by the first grant of its kind to focus on a molecular pathway that underlies many cancers rather than on a cancer in a particular organ or tissue in the body. [More]
Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. [More]
Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. [More]
Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

The National Cancer Institute has awarded Huntsman Cancer Institute at the University of Utah its Comprehensive Cancer Center status, the highest designation possible. [More]
Improved clinical management results in higher quality of life for patients with neurofibromatosis

Improved clinical management results in higher quality of life for patients with neurofibromatosis

A genetic disorder called neurofibromatosis (NF) causes benign tumors to grow on the brain, spinal cord, and other parts of the nervous system. [More]
Researchers map out surgical anatomy, approaches for auditory brainstem implant placement

Researchers map out surgical anatomy, approaches for auditory brainstem implant placement

A technique called auditory brainstem implantation can restore hearing for patients who can't benefit from cochlear implants. A team of US and Japanese experts has mapped out the surgical anatomy and approaches for auditory brainstem implantation in the June issue of Operative Neurosurgery, published on behalf of the Congress of Neurological Surgeons by Wolters Kluwer. [More]
Male genetic diversity declined due to wealth, power rather than `survival of fittest`

Male genetic diversity declined due to wealth, power rather than `survival of fittest`

The DNA you inherit from your parents contributes to the physical make-up of your body -- whether you have blue eyes or brown, black hair or red, or are male or female. [More]
Slow-growing tumors have treatment-resistant stem cells, shows study

Slow-growing tumors have treatment-resistant stem cells, shows study

Scientists are eager to make use of stem cells' extraordinary power to transform into nearly any kind of cell, but that ability also is cause for concern in cancer treatment. [More]
UT Southwestern researchers identify possible therapy to treat neurofibromatosis type 1

UT Southwestern researchers identify possible therapy to treat neurofibromatosis type 1

UT Southwestern Medical Center researchers have identified a possible therapy to treat neurofibromatosis type 1 or NF1, a childhood neurological disease characterized by learning deficits and autism that is caused by inherited mutations in the gene encoding a protein called neurofibromin. [More]
Advertisement
Advertisement